{
  "id": "conjugate-vaccine",
  "title": "Conjugate Vaccine",
  "lang": "en",
  "source_lang": "en",
  "summary": "A conjugate vaccine chemically links a bacterial sugar antigen to a carrier protein, improving immune responses and memory, particularly in infants and young children.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Polysaccharide–protein conjugate vaccine",
    "glycoconjugate vaccine"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/conjugate-vaccine/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/conjugate-vaccine/",
      "json": "https://aiwiki.page/zh/conjugate-vaccine.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A conjugate vaccine is a type of vaccine in which a carbohydrate antigen, usually a polysaccharide from the outer capsule of a bacterium, is chemically attached to a carrier protein. This linkage changes how the immune system responds to the carbohydrate, enabling more effective responses in infants and promoting immunological memory. Conjugate vaccines are used against infections caused by Haemophilus influenzae type b, pneumococci, meningococci, and Salmonella Typhi. They are a form of subunit vaccine: they contain selected components of a pathogen rather than a whole organism."
    },
    {
      "heading": "Biological basis",
      "text": "Why bacterial capsules are vaccine targets\n\nMany disease-causing bacteria have an outer capsule composed of polysaccharides, long chains of sugar units. Capsules can help bacteria evade immune defenses, including engulfment by immune cells. An antibody directed against the capsule can help the body recognize and eliminate the bacterium.\n\nPurified capsular polysaccharides can themselves be used as vaccines. However, many provoke predominantly T-cell-independent immune responses. They can activate certain B cells without the conventional assistance of helper T cells, but generally produce limited immunological memory and relatively weak responses in children younger than about two years. Repeated doses do not reliably produce the strong booster responses associated with T-cell-dependent antigens.\n\nHow conjugation changes the response\n\nConjugation physically links the sugar antigen to a protein that can recruit helper T cells. A B cell that recognizes the carbohydrate binds and takes up the linked sugar–protein complex. It then processes the carrier protein and displays protein-derived peptides on major histocompatibility complex class II molecules.\n\nHelper T cells recognize these displayed peptides and provide signals that support B-cell proliferation and differentiation. Through this process, often called linked recognition, a carbohydrate-specific B cell receives help from a protein-specific T cell.\n\nThe resulting response can support:\n\n- Antibody class switching, including production of IgG.\n- Affinity maturation, which improves antibody binding.\n- Formation of memory B cells.\n- Production of longer-lived antibody-secreting cells.\n- Stronger responses to subsequent vaccine doses.\n\nThe key feature is the physical linkage between carbohydrate and protein. Simply mixing an unconjugated polysaccharide with a protein does not reproduce the same effect."
    },
    {
      "heading": "Composition and manufacture",
      "text": "Conjugate vaccines contain a defined polysaccharide or shorter carbohydrate fragment joined to a carrier protein through a controlled chemical process. Common carriers include tetanus toxoid, diphtheria toxoid, and CRM197, a nontoxic variant of diphtheria toxin. Other carrier proteins are used in particular products.\n\nManufacturing must preserve carbohydrate structures recognized by protective antibodies while maintaining suitable linkage to the carrier. Important quality attributes include carbohydrate chain length, the ratio of carbohydrate to protein, the amount of unbound material, and product stability.\n\nSome formulations also contain a vaccine adjuvant. An adjuvant enhances immune responses through mechanisms distinct from conjugation; the two are not interchangeable.\n\nA conjugate vaccine may be monovalent, targeting one capsular type, or multivalent, containing conjugates against several types. A serotype is a variant distinguished by its antigenic properties. Higher valency indicates a larger number of included types, not necessarily stronger protection against every type.\n\nThe carrier protein primarily supplies T-cell help. Its presence does not automatically make a conjugate vaccine a substitute for routine vaccination against the disease from which that carrier originated."
    },
    {
      "heading": "Main applications",
      "text": "Vaccine group | Target and principal purpose | Important distinction\nHib conjugate vaccines | Prevent invasive disease caused by Haemophilus influenzae type b | Do not protect against every strain of H. influenzae\nPneumococcal conjugate vaccines | Prevent disease caused by included serotypes of Streptococcus pneumoniae | Coverage depends on the serotypes in the formulation\nMeningococcal conjugate vaccines | Prevent invasive disease caused by included meningococcal serogroups | Common products target A, C, W, and Y, individually or in combinations\nTyphoid conjugate vaccines | Prevent typhoid fever caused by Salmonella Typhi | Do not provide equivalent protection against all causes of enteric fever\n\nHib, pneumococcal, and meningococcal infections can cause meningitis and bloodstream infection, including sepsis. Pneumococci also cause pneumonia and otitis media, although protection against these conditions depends on which organisms and serotypes cause them.\n\nNot all vaccines against these bacteria are conjugate vaccines. Unconjugated polysaccharide products also exist. Meningococcal group B vaccines generally use protein antigens rather than the capsular polysaccharide–protein approach."
    },
    {
      "heading": "Historical development and population effects",
      "text": "Experimental work in the early twentieth century established that attaching bacterial carbohydrates to proteins could change their immunological properties. Clinical development later focused on overcoming the poor performance of plain polysaccharide vaccines in infants.\n\nThe first Hib conjugate vaccine was licensed in the United States in 1987. Subsequent Hib products supported routine infant vaccination. Their introduction was followed by large reductions in invasive Hib disease in countries with high vaccine coverage.\n\nThe first pneumococcal conjugate vaccine was licensed in the United States in 2000. Later formulations expanded the number of included serotypes. Meningococcal conjugate vaccines became important tools in national immunization programs and epidemic control, including vaccination against meningococcal group A in the African meningitis belt. Typhoid conjugate vaccines extended the approach to prevention of typhoid fever, including in young children.\n\nFor some organisms and vaccine formulations, conjugate vaccination reduces carriage in the nose and throat as well as disease. Reduced carriage can decrease transmission and provide indirect protection to unvaccinated people. This effect is well established for Hib and vaccine-type pneumococci, but its extent varies by pathogen and product; it cannot be assumed for every conjugate vaccine."
    },
    {
      "heading": "Limitations and safety",
      "text": "Conjugation improves the immune response to selected carbohydrate antigens but does not eliminate all limitations of vaccination.\n\nProtection is antigen-specific. A vaccine may cover only some of the circulating capsular types. Following pneumococcal vaccination, non-vaccine serotypes can account for a greater proportion of carriage or disease, a phenomenon known as serotype replacement. Its effect on total disease burden varies between populations.\n\nProtection can wane. Immune memory does not necessarily maintain continuously protective circulating antibody concentrations. This distinction matters for infections that can progress rapidly. Dose schedules and booster policies therefore differ by vaccine, age group, and national program.\n\nResponses vary between recipients. Age, immunodeficiency, and immunosuppression can affect vaccine responses. Conjugate vaccines cannot guarantee protection in every recipient.\n\nManufacture is complex. Producing and testing multiple distinct conjugates adds technical complexity and cost. Procurement, storage, and delivery requirements can influence access within a health system.\n\nConjugate vaccines are non-live and cannot cause the bacterial infections they are designed to prevent. Common adverse reactions include injection-site pain, redness, swelling, and transient fever. Severe allergic reactions, including anaphylaxis, are rare. Safety assessment is product-specific and continues after authorization through pharmacovigilance and other surveillance systems."
    }
  ],
  "links": [
    "vaccine",
    "protein",
    "immune-system",
    "subunit-vaccine",
    "bacteria",
    "polysaccharide",
    "antibody",
    "b-cell",
    "t-cell",
    "vaccine-adjuvant",
    "sepsis",
    "pneumonia",
    "otitis-media",
    "united-states",
    "herd-immunity",
    "immunodeficiency",
    "immunosuppression",
    "health-system",
    "fever",
    "anaphylaxis",
    "pharmacovigilance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}